Valued at $90.3 billion by market cap, Bristol-Myers Squibb Company (BMY) is a top biopharmaceutical company that focuses on cancer, inflammation, cardiovascular disease, and other serious diseases. Founded in 1887 and headquartered in Princeton, New Jersey, its leading drug, Opdivo, drives its oncology portfolio alongside drugs like Revlimid and Eliquis.
Shares of the biopharma company have underperformed the broader market considerably over the past year. BMY has declined 34.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 28.9%. In 2024, Bristol-Myers Squibb’s stock fell 14%, while the SPX is up 11.1% on a YTD basis.
